age-related macular degeneration

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Regeneron
Eylea
age-related macular degeneration
FDA
Flag link:
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Fierce Biotech
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration
Flag link:
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Flag link:
Gemini axes CSO and 20% of staff to focus on late-phase plans
Gemini axes CSO and 20% of staff to focus on late-phase plans
Fierce Biotech
Gemini Therapeutics
layoffs
gene therapy
CSO
age-related macular degeneration
Flag link:
FDA approves first biosimilar to top-selling eye drug Lucentis
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
Flag link:
Outlook heads to regulators with eye-friendly Avastin
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
Flag link:
3 Biotech Stocks With Big Catalysts in June
3 Biotech Stocks With Big Catalysts in June
Motley Fool
Corbus Pharmaceuticals
lenabasum
clinical trials
Gemini Therapeutics
age-related macular degeneration
Intellia Therapeutics
hATTR-pn
Flag link:
Gyroscope bags $148M for AMD gene therapy trials, mulls IPO
Gyroscope bags $148M for AMD gene therapy trials, mulls IPO
Fierce Biotech
Gyroscope
gene therapy
IPOs
age-related macular degeneration
Flag link:
Genentech Could Regain the Blindness-Related Disease Market with New Treatment
Genentech Could Regain the Blindness-Related Disease Market with New Treatment
BioSpace
Roche
Genentech
clinical trials
faricimab
age-related macular degeneration
nAMD
Flag link:
RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
Pharmaceutical Business Review
RIBOMIC
AJU Pharm Co
Korea
RBM-007
age-related macular degeneration
Flag link:
3 Biotech Stocks That Soared Last Week
3 Biotech Stocks That Soared Last Week
Motley Fool
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Flag link:
Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
An eye drop for macular degeneration shows promise in animal studies
An eye drop for macular degeneration shows promise in animal studies
Fierce Biotech
age-related macular degeneration
Macregen
Flag link:
Apellis touts new data for eye drug hopeful
Apellis touts new data for eye drug hopeful
Biopharma Dive
Apellis
eye health
APL-2
age-related macular degeneration
Flag link:
LumiThera wins Health Canada nod for photobiomodulation trial
LumiThera wins Health Canada nod for photobiomodulation trial
Mass Device
LumiThera
Canada
photobiomodulation
devices
age-related macular degeneration
Flag link:
The Next Blockbusters Could Be Balms For Aging Eyes
The Next Blockbusters Could Be Balms For Aging Eyes
Investors.com
age-related macular degeneration
Bayer
Regeneron
Ophthotech
Allergan
Novartis
Applied Genetic Technologies
Avalanche Biotechnologies
Roche
Lucentis
Eylea
Flag link:
Italy's move to fund unapproved use of Roche's Avastin alarms the industry
Italy's move to fund unapproved use of Roche's Avastin alarms the industry
Fierce Pharma
Italy
Roche
Avastin
age-related macular degeneration
Flag link:
Using Avastin for Eye Disorder Could Save U.S. $3 Billion
Using Avastin for Eye Disorder Could Save U.S. $3 Billion
Bloomberg
Avastin
Roche
Lucentis
age-related macular degeneration
diabetic macular edema
Flag link:
StemCells advances HuCNS-SC clinical trial to final cohort
StemCells advances HuCNS-SC clinical trial to final cohort
The Fly on the Wall
StemCells
HuCNS-SC
clinical trials
age-related macular degeneration
Flag link:

Pages